Italia markets closed
Dow Jones
39.135,33 +23,17 (+0,06%) Nasdaq
17.734,83 +17,17 (+0,10%) Nikkei 225
39.667,07 +493,92 (+1,26%) EUR/USD
1,0680 -0,0035 (-0,33%) Bitcoin EUR
56.931,13 -1.184,50 (-2,04%) CMC Crypto 200
1.265,41 -18,37 (-1,43%)
NBIX Dec 2024 150.000 put
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 10:30AM EDT. Mercato aperto.
| Chiusura precedente | 20,00 |
| Aperto | 20,00 |
| Denaro | 16,10 |
| Domanda | 18,90 |
| Prezzo d'esercizio | 150,00 |
| Scadenza | 2024-12-20 |
| Min-Max giorno | 20,00 - 20,00 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | N/D |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.